298 related articles for article (PubMed ID: 26530732)
1. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma.
Jarnbring F; Kashani A; Björk A; Hoffman T; Krawiec K; Ljungman P; Lund B
Br J Oral Maxillofac Surg; 2015 Dec; 53(10):1007-11. PubMed ID: 26530732
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.
Then C; Hörauf N; Otto S; Pautke C; von Tresckow E; Röhnisch T; Baumann P; Schmidmaier R; Bumeder I; Oduncu FS
Onkologie; 2012; 35(11):658-64. PubMed ID: 23147542
[TBL] [Abstract][Full Text] [Related]
4. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
Assael LA
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
[TBL] [Abstract][Full Text] [Related]
5. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
6. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
7. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Thomas C; Spanidis M; Engel C; Roos FC; Frees S; Neisius A; Hampel C; Rubenwolf P; Thüroff JW; Walter C; Miederer M
Clin Oral Investig; 2016 May; 20(4):753-8. PubMed ID: 26307268
[TBL] [Abstract][Full Text] [Related]
8. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
Carlson ER; Basile JD
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.
Bagan J; Scully C; Sabater V; Jimenez Y
Oral Oncol; 2009 Jul; 45(7):551-4. PubMed ID: 19251474
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Thumbigere-Math V; Tu L; Huckabay S; Dudek AZ; Lunos S; Basi DL; Hughes PJ; Leach JW; Swenson KK; Gopalakrishnan R
Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
[TBL] [Abstract][Full Text] [Related]
11. The care and management of bisphosphonate--associated osteonecrosis of the jaw in the patient with multiple myeloma: a case study.
Teah MJ; Syme SL; Scheper M; Weikel DS
J Dent Hyg; 2013 Aug; 87(4):181-7. PubMed ID: 23986411
[TBL] [Abstract][Full Text] [Related]
12. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
Dodson TB
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
[TBL] [Abstract][Full Text] [Related]
13. [Diabetes mellitus and bisphosphonate-related osteonecrosis of the jaws].
Urade M
Clin Calcium; 2009 Sep; 19(9):1332-8. PubMed ID: 19721206
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases.
Pelaz A; Junquera L; Gallego L; García-Consuegra L; García-Martínez L; Cutilli T; Olay S
Acta Otorrinolaringol Esp; 2015; 66(3):139-47. PubMed ID: 25308796
[TBL] [Abstract][Full Text] [Related]
15. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital.
Taylor T; Bryant C; Popat S
Br Dent J; 2013 Apr; 214(7):E18. PubMed ID: 23579162
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
Rugani P; Luschin G; Jakse N; Kirnbauer B; Lang U; Acham S
Clin Oral Investig; 2014; 18(2):401-7. PubMed ID: 23749244
[TBL] [Abstract][Full Text] [Related]
18. Dental implications of bisphophonate-related osteonecrosis.
Saldanha S; Shenoy VK; Eachampati P; Uppal N
Gerodontology; 2012 Sep; 29(3):177-87. PubMed ID: 22486711
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
[TBL] [Abstract][Full Text] [Related]
20. Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients.
Veszelyné Kotán E; Bartha-Lieb T; Parisek Z; Meskó A; Vaszilkó M; Hankó B
BMJ Open; 2019 May; 9(5):e025600. PubMed ID: 31122970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
